Vivoryon Therapeutics N.V.

BATS-CHIXE:VVYA Stock Report

Market Cap: €62.0m

Vivoryon Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BATS-CHIXE:VVYA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Mar 24Sell€7,734Michael SchaefferIndividual3,867€2.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VVYA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,891,2677.26%
Individual Insiders3,015,59411.6%
Institutions5,643,90721.7%
General Public15,516,04159.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 19 shareholders own 40.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
C. Christiansen
2,625,235€6.2m0%no data
7.67%
Danish Research Foundation., Endowment Arm
1,999,547€4.8m0%no data
7.26%
T&W Holding A/S
1,891,267€4.5m-5.42%no data
4.04%
Mackenzie Investments Europe Limited
1,053,206€2.5m0%0.08%
2.95%
Lupus alpha Investment GmbH
769,500€1.8m0%0.42%
2.3%
UBS Asset Management AG
599,168€1.4m0%no data
1.95%
JPMorgan Chase & Co, Brokerage and Securities Investments
507,469€1.2m0%no data
1.36%
Erich Platzer
355,409€845.9k0%no data
1.24%
Lemanik S.A., Asset Management Arm
323,658€770.3k0%0.27%
0.65%
Matejka & Partner Asset Management GmbH
169,380€403.1k0%0.88%
0.27%
Vogt Asset Management Trust Reg.
70,000€166.6k250%0.1%
0.19%
amandea Vermögensverwaltung AG
50,000€119.0k0%0.31%
0.18%
Mainfirst Affiliated Fund Managers (Deutschland) GmbH
47,500€113.0k0%0.07%
0.13%
Frank Weber
33,950€80.8k0%no data
0.084%
Azimut Capital Management Sgr SpA
22,000€52.4k0%no data
0.058%
Quadriga Asset Managers, Sgiic, S.A
15,000€35.7k0%0.11%
0.048%
GVC Gaesco Gestion SGIIC SA
12,479€29.7k0%no data
0.019%
Gestys SA
5,000€11.9k-23.1%0.48%
0.0038%
Claudia Riedl
1,000€2.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/16 20:27
End of Day Share Price 2024/07/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivoryon Therapeutics N.V. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander GalitsaHauck Aufhäuser Investment Banking
Lucy-Emma Mary Codrington-BartlettJefferies LLC
Christian EhmannWarburg Research GmbH